Article
Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.
Lung cancer (Amsterdam, Netherlands) - 1 Sept 2017
Ou Sai-Hong Ignatius, Horn Leora, Cruz Marcelo, Vafai Davood, Lovly Christine M, Spradlin Allison, Williamson Michael J, Dagogo-Jack Ibiayi, Johnson Adrienne, Miller Vincent A, Gadgeel Shirish, Ali Siraj M, Schrock Alexa B
Abstract excerpt
Resistance to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancers (NSCLCs) with activating EGFR mutations generally involve development of acquired secondary or tertiary EGFR mutations, such as T790M or C797S. However, case reports have demonstrated that actionable receptor tyrosine kinase fusions such as EML4-ALK, CCDC6-RET, and FGFR3-TACC3 can potentially confer resistance to EGFR TKIs. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.